Literature DB >> 24331919

Inhibition of telomerase induces alternative lengthening of telomeres during human esophageal carcinogenesis.

Angela Queisser1, Steffen Heeg2, Michaela Thaler3, Alexander von Werder3, Oliver G Opitz4.   

Abstract

Immortalization is an important step toward the malignant transformation of human cells and is critically dependent upon telomere maintenance. Two mechanisms are known to maintain human telomeres. The process of telomere maintenance is either mediated through activation of the enzyme telomerase or through an alternative mechanism of telomere lengthening called alternative lengthening of telomeres (ALT). Whereas 85% of all human tumors show reactivation of telomerase, the remaining 15% are able to maintain telomeres via ALT. Telomerase inhibitors are already investigated in clinical trials, although the regulation as well as potential coexistence and redundancy of both telomere maintenance mechanisms during distinct steps of carcinogenesis are poorly understood. Herein, we demonstrate that telomerase activity and ALT alternate in a cell cycle dependent fashion in human esophageal epithelial cells, and can coexist in a genetically defined model of oral-esophageal squamous carcinogenesis. Moreover, we show that immortalized premalignant cells as well as cancer cells are able to switch from telomerase activation to ALT upon inhibition of telomerase. This indicates that cancer cells treated with telomerase inhibitors can use alternative and adaptive ways to maintain their telomeres and thereby escape telomere-based therapeutic strategies.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALT; Esophageal cancer; telomerase inhibition

Mesh:

Substances:

Year:  2013        PMID: 24331919     DOI: 10.1016/j.cancergen.2013.10.001

Source DB:  PubMed          Journal:  Cancer Genet


  15 in total

Review 1.  Telomeres and telomerase in the clinical management of colorectal cancer.

Authors:  C Piñol-Felis; T Fernández-Marcelo; J Viñas-Salas; C Valls-Bautista
Journal:  Clin Transl Oncol       Date:  2016-10-19       Impact factor: 3.405

Review 2.  Telomerase lost?

Authors:  James M Mason; Thomas A Randall; Radmila Capkova Frydrychova
Journal:  Chromosoma       Date:  2015-07-11       Impact factor: 4.316

3.  SLX4IP N-terminus dictates telomeric localization in ALT-like castration-resistant prostate cancer cell lines.

Authors:  Tawna L Mangosh; Magdalena M Grabowska; Derek J Taylor
Journal:  Prostate       Date:  2021-09-07       Impact factor: 4.104

4.  ALTernative Telomere Maintenance and Cancer.

Authors:  Robert L Dilley; Roger A Greenberg
Journal:  Trends Cancer       Date:  2015-10-01

5.  SLX4IP Promotes Telomere Maintenance in Androgen Receptor-Independent Castration-Resistant Prostate Cancer through ALT-like Telomeric PML Localization.

Authors:  Tawna L Mangosh; Wisam N Awadallah; Magdalena M Grabowska; Derek J Taylor
Journal:  Mol Cancer Res       Date:  2020-11-13       Impact factor: 6.333

Review 6.  Treating Cancer by Targeting Telomeres and Telomerase.

Authors:  Marko Ivancich; Zachary Schrank; Luke Wojdyla; Brandon Leviskas; Adijan Kuckovic; Ankita Sanjali; Neelu Puri
Journal:  Antioxidants (Basel)       Date:  2017-02-19

Review 7.  Telomerase reverse transcriptase moonlights: Therapeutic targets beyond telomerase.

Authors:  Yoshiko Maida; Kenkichi Masutomi
Journal:  Cancer Sci       Date:  2015-10-21       Impact factor: 6.716

Review 8.  Variations in telomere maintenance and the role of telomerase inhibition in gastrointestinal cancer.

Authors:  Steffen Heeg
Journal:  Pharmgenomics Pers Med       Date:  2015-12-04

9.  Switch telomerase to ALT mechanism by inducing telomeric DNA damages and dysfunction of ATRX and DAXX.

Authors:  Yang Hu; Guang Shi; Laichen Zhang; Feng Li; Yuanling Jiang; Shuai Jiang; Wenbin Ma; Yong Zhao; Zhou Songyang; Junjiu Huang
Journal:  Sci Rep       Date:  2016-08-31       Impact factor: 4.379

10.  Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma.

Authors:  Patricia Reyes-Uribe; Maria Paz Adrianzen-Ruesta; Zhong Deng; Ileabett Echevarria-Vargas; Ilgen Mender; Steven Saheb; Qin Liu; Dario C Altieri; Maureen E Murphy; Jerry W Shay; Paul M Lieberman; Jessie Villanueva
Journal:  Oncogene       Date:  2018-04-26       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.